Reports Q3 revenue $193.9M, consensus $192.7M. “In this transitional year, we are focused on bringing the benefits of our #1 rated automated insulin delivery system to more people living with diabetes worldwide, providing customer care excellence and advancing our scalability initiatives,” said John Sheridan, president and chief executive officer. “There is a large and growing opportunity for Tandem’s technology to drive greater use of automated insulin delivery worldwide, and we are advancing our efforts to expand this adoption through our near-term portfolio of diabetes solutions.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TNDM:
- Tandem Diabetes price target lowered to $18 from $33 at BofA
- Tandem Diabetes initiated with a Market Perform at Leerink
- Tandem Diabetes price target lowered to $23 from $31 at Citi
- Tandem Diabetes price target lowered to $45 from $47 at Jefferies
- DexCom price target lowered to $98 from $131 at Morgan Stanley